Comerica Bank Grows Stake in Zimmer Biomet Holdings, Inc. (ZBH)

Comerica Bank increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 115,881 shares of the medical equipment provider’s stock after purchasing an additional 2,708 shares during the period. Comerica Bank owned approximately 0.06% of Zimmer Biomet Holdings worth $14,062,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. Bronfman E.L. Rothschild L.P. raised its holdings in shares of Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in Zimmer Biomet Holdings by 3.9% during the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 33 shares during the last quarter. BB&T Investment Services Inc. purchased a new stake in Zimmer Biomet Holdings during the second quarter valued at approximately $144,000. Sandy Spring Bank increased its holdings in Zimmer Biomet Holdings by 5.4% during the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 66 shares during the last quarter. Finally, Grove Bank & Trust increased its holdings in Zimmer Biomet Holdings by 346.1% during the second quarter. Grove Bank & Trust now owns 1,316 shares of the medical equipment provider’s stock valued at $169,000 after buying an additional 1,021 shares during the last quarter. 85.44% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Comerica Bank Grows Stake in Zimmer Biomet Holdings, Inc. (ZBH)” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/11/16/comerica-bank-grows-stake-in-zimmer-biomet-holdings-inc-zbh.html.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down $1.13 during trading hours on Thursday, hitting $111.08. 1,149,900 shares of the company were exchanged, compared to its average volume of 1,364,914. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. Zimmer Biomet Holdings, Inc. has a 12-month low of $98.20 and a 12-month high of $133.49. The company has a market capitalization of $22,719.51, a price-to-earnings ratio of 13.90, a price-to-earnings-growth ratio of 1.74 and a beta of 1.17.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. Zimmer Biomet Holdings’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.79 EPS. equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current year.

ZBH has been the subject of a number of research reports. BidaskClub cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Cantor Fitzgerald set a $137.00 target price on shares of Zimmer Biomet Holdings and gave the company a “hold” rating in a report on Thursday, July 27th. Canaccord Genuity cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and reduced their target price for the company from $141.00 to $135.00 in a report on Friday, July 28th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $135.00 target price on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $137.00 target price on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Friday, July 28th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $133.71.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply